Regeneron Joins Fight to Combat Coronavirus

http://thebcw.org/wp-content/uploads/2020/02/regeneron.jpg

Tarrytown -based Regeneron Pharmaceuticals, Inc. has announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which was recently declared a global public health emergency by the World Health Organization.

Regeneron has a number of active collaborations with HHS’s Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response, including a collaboration to advance Regeneron’s investigational Ebola treatment REGN-EB3

The agreement between the HHS and Regeneron, originally established in 2017, is focused on discovery, research, development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health, now including the Influenza virus and 2019-nCoV. The effort utilizes Regeneron’s proprietary VelociSuite^® technologies which are particularly well-suited for use in quickly-developing outbreak situations, as was done for Ebola.